1. Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019-2020.
- Author
-
Williams T, Jackson S, Barr I, Bi S, Bhiman J, Ellis J, von Gottberg A, Lindstrom S, Peret T, Rughooputh S, Viegas M, Hirve S, Zambon M, Zhang W, Dia N, Razanazatovo N, Al-Nabet ADMH, Abubakar A, Tivane A, Barakat A, Naguib A, Aziz A, Vicari A, Moen A, Govindakarnavar A, Hall A, Darmaa B, Nathalie B, Herring B, Caetano BC, Whittaker B, Baumeister E, Nakouné E, Guthrie E, Inbanathan F, Nair H, Campbell H, Kadjo HA, Oumzil H, Heraud JM, Mott JA, Namulondo J, Leite J, Nahapetyan K, Al Ariqi L, Gazo MHI, Chadha M, Pisareva M, Venter M, Siqueira MM, Lumandas M, Niang M, Albuaini M, Salman M, Oberste S, Srikantiah P, Tang P, Couto P, Smith P, Coyle PV, Dussart P, Nguyen PN, Okada PA, Wijesinghe PR, Samuel R, Brown R, Pebody R, Fasce R, Jha R, Lindstrom S, Gerber S, Potdar V, Dong X, and Deng YM
- Subjects
- United States, Humans, Laboratories, World Health Organization, Australia, Respiratory Syncytial Virus, Human genetics, Viruses
- Abstract
Background: External quality assessments (EQAs) for the molecular detection of human respiratory syncytial virus (RSV) are necessary to ensure the standardisation of reliable results. The Phase II, 2019-2020 World Health Organization (WHO) RSV EQA included 28 laboratories in 26 countries. The EQA panel evaluated performance in the molecular detection and subtyping of RSV-A and RSV-B. This manuscript describes the preparation, distribution, and analysis of the 2019-2020 WHO RSV EQA., Methods: Panel isolates underwent whole genome sequencing and in silico primer matching. The final panel included nine contemporary, one historical virus and two negative controls. The EQA panel was manufactured and distributed by the UK National External Quality Assessment Service (UK NEQAS). National laboratories used WHO reference assays developed by the United States Centers for Disease Control and Prevention, an RSV subtyping assay developed by the Victorian Infectious Diseases Reference Laboratory (Australia), or other in-house or commercial assays already in use at their laboratories., Results: An in silico analysis of isolates showed a good match to assay primer/probes. The panel was distributed to 28 laboratories. Isolates were correctly identified in 98% of samples for detection and 99.6% for subtyping., Conclusions: The WHO RSV EQA 2019-2020 showed that laboratories performed at high standards. Updating the composition of RSV molecular EQAs with contemporary strains to ensure representation of circulating strains, and ensuring primer matching with EQA panel viruses, is advantageous in assessing diagnostic competencies of laboratories. Ongoing EQAs are recommended because of continued evolution of mismatches between current circulating strains and existing primer sets., Competing Interests: No conflict of interest is declared by authors., (© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF